ADHD medication in autistic people
What placebo-controlled trials and reviews show about methylphenidate, atomoxetine, guanfacine and clonidine for ADHD traits in autistic children, how the results compare with ADHD alone, which side effects lead people to stop, and how little is known about adults.
Some autistic people also have ADHD. This page is about what tests of ADHD medicines have found in autistic people, which side effects come up, and what is still unknown.
What has been tested Established
The evidence rests on a small number of short trials in children. A 2021 meta-analysis searched for placebo-controlled trials in autistic people under 25 of stimulants (methylphenidate or amphetamines), atomoxetine, alpha-2 agonists and several other medicines. Among the 25 trials it included were 4 of methylphenidate, 4 of atomoxetine and 1 of guanfacine, and none of amphetamines.1 Another 2021 review counted 9 controlled trials of ADHD medicines with at least 10 participants, holding 430 children between them, with samples from 10 to 128.2 Clonidine was tested in two crossover trials in 1992: one with 8 boys who had not responded to or tolerated other medicines, and one using a skin patch with 9 males aged 5 to 33.3,4
Most of the 9 trials in the 2021 review enrolled only children with an intellectual disability and high levels of irritability, and almost all measured only hyperactivity.2 The four methylphenidate trials in the 2017 Cochrane review held 113 children aged 5 to 13, 83% of them boys, all in the United States, and gave each dose for one week.5
Scientists test a medicine by comparing it with a placebo. A placebo is a fake pill that looks the same. Only a few such tests have been done in autistic people with ADHD traits. Almost all of them were short, and almost all were in children.1,2
One review found 4 tests of methylphenidate, 4 of atomoxetine and 1 of guanfacine. It found no tests of amphetamines.1 Two tiny tests of clonidine were done in 1992. They had 8 boys and 9 males.3,4 In most tests, the children also had an intellectual disability. Most tests only measured how active and restless the children were.2 In the methylphenidate tests, most children were boys and all lived in the United States. Each dose was given for one week.5
Several systematic reviews agree on the size and make-up of the trial evidence. They describe the same small set of trials, so their agreement is about what exists rather than an independent check of results.
This entry summarizes research. It gives no doses and makes no recommendation for any person. Decisions about medication belong with a prescriber who knows the person.
A study that compares a medicine with an inactive look-alike, usually without the participants or raters knowing which is which.
A trial in which each participant takes the medicine and the placebo in turn, so each person is compared with themselves.
Several reviews agree on which tests have been done. They all look at the same small set of tests.
This page is about research. It gives no doses and tells no one what to take. Choices about medicine are for a person and their doctor.
A test where each person takes the medicine for a while and the fake pill for a while. Each person is compared with themselves.
Methylphenidate Established
Pooled across trials, methylphenidate reduced hyperactivity in autistic children, by a standardized mean difference of 0.81 on teacher ratings and 0.63 on parent ratings. Its effect on inattention was smaller, about 0.3 to 0.36. The evidence was rated low or very low in quality.1 The Cochrane review found a similar teacher-rated effect on hyperactivity at high doses (0.78, from 4 studies and 73 children). On teacher ratings of social interaction and repetitive behavior, it found no clear effect either way, from low or very low quality evidence.5 It judged three of the four trials at high risk of bias from selective reporting, and all four at unclear risk for blinding, because side effects could let parents and teachers guess who was taking the medicine.5
The largest methylphenidate trial, run by the RUPP Autism Network, enrolled 72 children aged 5 to 14 with marked hyperactivity. After a test-dose week, 66 went on to the comparison with placebo. Effect sizes ranged from 0.20 to 0.54 depending on dose and rater, and 35 of the 72 children (49%) were counted as responders.6 Smaller trials also found benefit, with a mixed picture of side effects. In 13 children, 8 responded.7 In 10 children aged 7 to 11, the improvement was modest.8 In 24 community-recruited children (19 boys) with an average IQ of 85, hyperactive and impulsive behavior fell at home and at school.9 In 14 preschoolers, 12 of them autistic, half responded and half had side effects, including more repetitive movements, upset stomach, sleep problems and mood swings.10
Methylphenidate is a stimulant. Reviews found it made autistic children less overactive, as rated by teachers and parents.1,5 It helped attention less.1 It did not clearly change autistic traits like social skills, either for better or worse.5
The biggest methylphenidate test had 72 children. About half of them, 35, were helped.6 Smaller tests also found some benefit, along with some side effects.7,8,9 In 14 young children, half were helped. Half had side effects, like upset stomach, sleep problems and mood swings.10
Three meta-analyses agree that methylphenidate reduces hyperactivity in autistic children. They pool largely the same four small, short crossover trials from the United States, mostly in boys, so the reviews are not independent replications of each other; the trials themselves come from different research groups and agree. The reviews rate the evidence low or very low in quality. The single-trial details below are emerging on their own.
A way of putting results from different rating scales on one scale. Around 0.2 is usually called small, 0.5 medium and 0.8 large.
Three reviews agree it helps with being very active. But they mostly look at the same four small, short tests, and they say the tests are not high quality.
Compared with ADHD alone Emerging
Whether these medicines work less well in autistic people is unsettled. The RUPP authors judged the response to methylphenidate smaller than in typically developing children with ADHD.6 A 2013 meta-analysis put the pooled effect at 0.67 and called it slightly lower than estimates for ADHD alone.11 A 2021 review judged the effect on hyperactivity of methylphenidate and atomoxetine lower than in non-autistic people, and guanfacine's higher. It found treatment better than placebo in every one of the 9 trials, but poorer results in people with an intellectual disability or with mood swings; most of the trials enrolled children with an intellectual disability.2
Other figures overlap. A large network meta-analysis of 133 trials of ADHD medicines in general put methylphenidate's effect in children and adolescents at 0.78 on clinician ratings and 0.82 on teacher ratings.12 The pooled teacher-rated figure in autistic children, 0.81, is similar, but its confidence interval runs from 0.19 to 1.43, and the largest single autism trial found smaller effects (0.20 to 0.54).1,6 Most autism trials were short crossovers, and pooling them needs an assumption about how each child's scores on and off the medicine relate; the Cochrane review used an assumed value for this.5 At one specialist clinic, children with ADHD improved about as much on methylphenidate whether or not they were also autistic, in a retrospective study of 174 children and a prospective one of 52.13 At one Dutch clinic for adults, 60 autistic and 226 non-autistic adults with ADHD had similar falls in symptoms.14 Neither clinic study was randomized.
Scientists are not sure if these medicines work less well in autistic people. Some researchers think methylphenidate helps autistic children a bit less than other children with ADHD.6,11,2 But the numbers from reviews are close to those for ADHD alone.12,1 At two clinics, people with ADHD improved about as much whether or not they were autistic.13,14 These clinic studies did not use a fake pill. Most tests in autistic children were crossover tests. Adding up their results needs a guess about how scores relate, so the numbers are less sure.5
No trial has randomized autistic and non-autistic children side by side. The comparisons are indirect, set trial results against those from other studies, or come from clinic records, and they disagree.
No test put autistic and non-autistic children side by side. Scientists compare results from different studies, and they do not agree.
Side effects and stopping Emerging
In the RUPP trial, side effects led 13 of 72 children (18%) to stop methylphenidate, and the authors reported side effects more often than in non-autistic children with ADHD.6 Irritability and social withdrawal appeared in some children in a smaller trial, mostly at the higher dose.7 In routine monitoring at one specialist clinic, not a randomized trial, sleep problems were the only side effect that emerged in autistic children with ADHD, and repetitive behaviors did not get worse.13 A 2013 meta-analysis found more reduced appetite, sleep problems, irritability, social withdrawal and low mood on methylphenidate than on placebo. The differences in risk ranged from 7 to 19 percentage points, and 14 for irritability.11 Its authors noted that some of these had not been found raised in trials of ADHD alone, and that some might be hard to tell apart from autistic traits or from calmer behavior.11
The Cochrane review found only reduced appetite, as rated by parents, clearly more common, from very low quality evidence. It also noted that the trials had already excluded children who could not tolerate a test dose, so the trials may understate side effects.5 Dropout because of side effects was higher on methylphenidate in one meta-analysis, though not significantly. A 2024 meta-analysis found a large effect of side effects on dropout.1,15 A 2019 review found that no trial had taken irritability as its main outcome, and judged the evidence too thin to say whether stimulants make irritability better or worse in autistic children with ADHD.16 The 2024 meta-analysis, pooling a similar small set of trials, reported that methylphenidate reduced irritability compared with placebo.15
Outside trials, prescription records show who keeps taking these medicines. In records from eight countries and regions covering about 1 million new users, autism was among the factors linked to stopping earlier in children aged 4 to 11 (hazard ratio 1.32). In the pooled analysis it was not a significant predictor from adolescence onwards, though it was in the US data for adults. Results varied a lot between countries, mostly because of the US figures, which the authors link to how health systems work. Differences between the sexes were limited.17 The records do not say why people stopped.
Some do. In the largest trial about 1 in 5 children stopped because of side effects, and the authors judged side effects more frequent than in ADHD alone. Other studies, of methylphenidate in children and adults and of atomoxetine in children, found side effects similar in kind or frequency to those in people without autism.6,13,14,20,22
In the biggest test, about 1 in 5 children stopped methylphenidate because of side effects.6 One review found more poor appetite, sleep problems, grumpiness, low mood and pulling away from others.11 Another review was only sure about poor appetite.5 At one clinic, poor sleep was the only side effect seen in autistic children.13 That review said the tests had already left out children who could not handle a first dose.5 No test has mainly looked at grumpiness, so scientists are not sure about it.16
In records from many countries, autistic children were more likely to stop ADHD medicine early. This was not clear for teenagers.17
Two meta-analyses of largely the same trials disagree on which side effects are raised and on dropout. Register studies show who stops, not why.
In Swedish national registers, children with both ADHD and autism were slightly more likely than children with ADHD alone to stop within 3 months (16% against 12%), and switched medicines more often, a difference driven by a minority who switched many times.18
Reviews of the same tests disagree about side effects. Records show who stops a medicine, but not why.
In Swedish national registers, children with both ADHD and autism were slightly more likely than children with ADHD alone to stop within 3 months (16% against 12%), and switched medicines more often, a difference driven by a minority who switched many times.18
Atomoxetine Emerging
Atomoxetine is not a stimulant. Pooling 3 trials with 241 children, it improved parent-rated hyperactivity (standardized mean difference 0.73) and inattention (0.53), with more nausea and vomiting, poorer sleep and reduced appetite than placebo. The authors judged the true size of the effect uncertain.19 Another meta-analysis put the parent-rated effect on hyperactivity lower, at 0.49, and found the teacher-rated effect not significant.1 A later review did not pool the two main trials at all, judging them too different.28 In a Dutch trial of 97 children aged 6 to 17 over 8 weeks, the main outcome, an ADHD rating scale, improved by 6.7 points more than on placebo, a significant difference. Clinicians rated 20.9% of children on atomoxetine as much improved against 8.7% on placebo, a difference that was not statistically significant. Side effects were reported by 81.3% against 65.3%, also not a significant difference, and the authors found them similar to those in trials of ADHD without autism.20
An American trial gave 128 children aged 5 to 14 atomoxetine, parent training, both, or placebo for 10 weeks. On parent ratings of ADHD traits, atomoxetine alone, atomoxetine with parent training, and parent training alone each beat placebo, with effect sizes of 0.57 to 0.98 across the three groups.21 Reduced appetite and tiredness were its main side effects, and most lasted 4 weeks or less.22 Five children on atomoxetine left early because of irritability or physical side effects.21 In a 24-week extension, 68% of those who had responded to atomoxetine still met the response criteria. Of 41 children who had not responded to placebo, 37% responded to 10 weeks of open-label atomoxetine. Within this small open-label group, those also receiving parent training responded more often (53% against 23%).23 An earlier pilot of 16 children found a large effect on hyperactivity (d 0.90); one child was readmitted to hospital for recurring violence while taking atomoxetine.24
Atomoxetine is an ADHD medicine that is not a stimulant. A review of 3 tests with 241 children found it helped with being overactive and with attention. It also caused more upset stomach, poor sleep and poor appetite.19 Another review found a smaller effect, and teachers did not see a clear change.1 In a Dutch test of 97 children, ADHD ratings improved more than with the fake pill.20 In an American test of 128 children, both atomoxetine and parent training helped.21 Most side effects lasted 4 weeks or less.22
Two independent trials, one Dutch and one American, found benefit. Meta-analyses differ on the size of the effect, the teacher-rated effect was not significant in one, and a later review judged the trials too different to pool. The American pilot and larger trial share authors, so they count as one. All are in children.
Two separate teams found it helped. But reviews disagree on how much, and one review said the tests were too different to add up. All tests were in children.
Guanfacine and clonidine Emerging
Guanfacine and clonidine are alpha-2 agonists, an older group of medicines first used for blood pressure. In the only placebo-controlled trial of extended-release guanfacine, 62 autistic children (53 boys), average age 8.5, took guanfacine or placebo for 8 weeks. Hyperactivity scores fell by 43.6% on guanfacine and 13.2% on placebo, an effect size of 1.67. Half the children on guanfacine were rated much improved, against 9.4% on placebo.25 Four children in each group left early. The commonest side effects were drowsiness, tiredness and reduced appetite; blood pressure fell over the first 4 weeks and then almost returned to its starting level, while pulse stayed lower.25 In the same trial, guanfacine reduced oppositional behavior and, more modestly, repetitive behavior. It did not improve sleep, and it did no better than placebo on anxiety, which was low at the start.26 A 2021 review found mood swings common with both guanfacine and methylphenidate.2
The clonidine evidence is older and smaller. In 8 boys who had not responded to or tolerated other medicines, teachers and parents rated some behavior better on clonidine, though a teacher scale of ADHD traits did not improve apart from oppositional behavior. Clinicians rating videotaped sessions saw no difference, and drowsiness increased.3 A skin-patch form was tested in 9 males aged 5 to 33 for a broader set of "hyperarousal" behaviors, and caused sleepiness and tiredness in the first 2 weeks.4
Guanfacine and clonidine were first used for high blood pressure. One test had 62 children, mostly boys. Those on guanfacine became much less overactive than those on the fake pill.25 Half were rated much better, compared with about 1 in 10 on the fake pill.25 Common side effects were sleepiness, tiredness and poor appetite.25 It did not help with sleep.26 Clonidine was tested in only 17 males, and it made some sleepy.3,4
Guanfacine rests on one trial of 62 children. The two clonidine trials are from 1992 and included 17 males in total.
Guanfacine was tested only once, in 62 children. The two clonidine tests are old and very small.
Adults Emerging
No placebo-controlled trial of ADHD medication in autistic adults was found as of October 2026. The Dutch clinic study that found similar results in autistic and non-autistic adults was retrospective. It excluded 79.3% of cases during selection, mostly for lack of documentation, and had little information on people who stopped.14 In an open-label trial, 15 autistic adults without an intellectual disability (80% men, average age 24.9) took long-acting methylphenidate for 6 weeks. Twelve (80%) were counted as responders; 13 had side effects, mostly mild to moderate, and one stopped because of them.27 With no placebo group, that response rate cannot be separated from expectation or natural change.
In the studies looked at here, no test of these medicines in autistic adults used a fake pill. One clinic looked back at its records and found adults with and without autism did about as well.14 But most records could not be used.14 In another study, 15 autistic adults took methylphenidate for 6 weeks. Twelve of them improved, and most had mild side effects.27 Without a fake pill, there is no way to tell how much was the medicine.
No placebo-controlled trial in autistic adults was found as of October 2026. The two adult studies are a retrospective clinic study and an open-label trial of 15 people.
A study in which everyone knows they are taking the medicine, with no placebo group for comparison.
In the studies looked at here, no test in autistic adults used a fake pill.
What is missing Established
A 2021 systematic review describes a shortage of trials in autistic people without an intellectual disability and in adults.2 Most participants were boys or men (83% in the Cochrane review's trials, 53 of 62 in the guanfacine trial, all of them in the clonidine trials), and none of the trials cited here reports whether results differ for girls or women.5,25,3,4 The quality of the trial evidence is rated low or very low, and there are almost no data on long-term use.1,5 None of the 9 trials in the 2021 review separated agitation from hyperactivity.2 The rating scales themselves are a gap: the Cochrane authors call for checking what size of change matters to autistic children, using scales validated for them.5
There are very few tests in autistic adults. There are also few in autistic people without an intellectual disability.2 The tests are short and not high quality. So little is known about taking these medicines for years.1,5 Most people in the tests were boys or men. No test cited here says whether results differ for girls or women.5,25,3,4 Scientists also need better ways to measure what change matters to autistic children.5
Independent reviews name the same gaps: low-quality, short trials, and few studies outside children with an intellectual disability.
Reviews agree on what is missing.
Sources
- 1Rodrigues R, Lai MC, Beswick A, et al. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis. Journal of Child Psychology and Psychiatry, 2021. https://doi.org/10.1111/jcpp.13305 ; https://pubmed.ncbi.nlm.nih.gov/32845025/
- 2Joshi G, Wilens T, Firmin ES, et al. Pharmacotherapy of attention deficit/hyperactivity disorder in individuals with autism spectrum disorder: A systematic review of the literature. Journal of Psychopharmacology, 2021. https://doi.org/10.1177/0269881120972336 ; https://pubmed.ncbi.nlm.nih.gov/33349107/
- 3Jaselskis CA, Cook EH, Fletcher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology, 1992. https://pubmed.ncbi.nlm.nih.gov/1479049/
- 4Fankhauser MP, Karumanchi VC, German ML, et al. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. Journal of Clinical Psychiatry, 1992. https://pubmed.ncbi.nlm.nih.gov/1548248/
- 5Sturman N, Deckx L, van Driel ML. Methylphenidate for children and adolescents with autism spectrum disorder. Cochrane Database of Systematic Reviews, 2017. https://doi.org/10.1002/14651858.CD011144.pub2 ; https://pubmed.ncbi.nlm.nih.gov/29159857/
- 6Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 2005. https://doi.org/10.1001/archpsyc.62.11.1266 ; https://pubmed.ncbi.nlm.nih.gov/16275814/
- 7Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders, 2000. https://doi.org/10.1023/a:1005548619694 ; https://pubmed.ncbi.nlm.nih.gov/11055460/
- 8Quintana H, Birmaher B, Stedge D, et al. Use of methylphenidate in the treatment of children with autistic disorder. Journal of Autism and Developmental Disorders, 1995. https://doi.org/10.1007/BF02179289 ; https://pubmed.ncbi.nlm.nih.gov/7559293/
- 9Pearson DA, Santos CW, Aman MG, et al. Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. Journal of Child and Adolescent Psychopharmacology, 2013. https://doi.org/10.1089/cap.2012.0096 ; https://pubmed.ncbi.nlm.nih.gov/23782128/
- 10Ghuman JK, Aman MG, Lecavalier L, et al. Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders. Journal of Child and Adolescent Psychopharmacology, 2009. https://doi.org/10.1089/cap.2008.0137 ; https://pubmed.ncbi.nlm.nih.gov/19702485/
- 11Reichow B, Volkmar FR, Bloch MH. Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders. Journal of Autism and Developmental Disorders, 2013. https://doi.org/10.1007/s10803-013-1793-z ; https://pubmed.ncbi.nlm.nih.gov/23468071/
- 12Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry, 2018. https://doi.org/10.1016/S2215-0366(18)30269-4 ; https://pubmed.ncbi.nlm.nih.gov/30097390/
- 13Santosh PJ, Baird G, Pityaratstian N, et al. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Child: Care, Health and Development, 2006. https://doi.org/10.1111/j.1365-2214.2006.00631.x ; https://pubmed.ncbi.nlm.nih.gov/16919137/
- 14Muit JJ, Bothof N, Kan CC. Pharmacotherapy of ADHD in adults with autism spectrum disorder: effectiveness and side effects. Journal of Attention Disorders, 2020. https://doi.org/10.1177/1087054719866255 ; https://pubmed.ncbi.nlm.nih.gov/31625426/
- 15Martins PLB, Torquato GCP, Dias GAPF, et al. Effectiveness of pharmacological interventions for managing ADHD symptoms in individuals with autism spectrum disorder: A systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2024. https://doi.org/10.1016/j.pnpbp.2024.111089 ; https://pubmed.ncbi.nlm.nih.gov/39004333/
- 16Ghanizadeh A, Molla MA, Olango GJ. The effect of stimulants on irritability in autism comorbid with ADHD: a systematic review. Neuropsychiatric Disease and Treatment, 2019. https://doi.org/10.2147/NDT.S194022 ; https://pubmed.ncbi.nlm.nih.gov/31239689/
- 17Brikell I, Astrup A, Wimberley T, et al. Psychiatric and neurological predictors of early ADHD medication discontinuation across the lifespan: a multinational study. BMJ Mental Health, 2026. https://doi.org/10.1136/bmjment-2025-302469 ; https://pubmed.ncbi.nlm.nih.gov/42392681/
- 18Garcia-Argibay M, Kuja-Halkola R, D'Onofrio BM, et al. Real-world ADHD pharmacological treatment patterns and their association with negative clinical outcomes in youth with comorbid autism: a Swedish population-based study. BMJ Mental Health, 2026. https://doi.org/10.1136/bmjment-2026-302902 ; https://pubmed.ncbi.nlm.nih.gov/42580811/
- 19Patra S, Nebhinani N, Viswanathan A, et al. Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta-analysis. Autism Research, 2019. https://doi.org/10.1002/aur.2059 ; https://pubmed.ncbi.nlm.nih.gov/30653855/
- 20Harfterkamp M, van de Loo-Neus G, Minderaa RB, et al. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2012. https://doi.org/10.1016/j.jaac.2012.04.011 ; https://pubmed.ncbi.nlm.nih.gov/22721596/
- 21Handen BL, Aman MG, Arnold LE, et al. Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2015. https://doi.org/10.1016/j.jaac.2015.08.013 ; https://pmc.ncbi.nlm.nih.gov/articles/PMC4625086/
- 22Tumuluru RV, Corbett-Dick P, Aman MG, et al. Adverse events of atomoxetine in a double-blind placebo-controlled study in children with autism. Journal of Child and Adolescent Psychopharmacology, 2017. https://doi.org/10.1089/cap.2016.0187 ; https://pubmed.ncbi.nlm.nih.gov/28509573/
- 23Smith T, Aman MG, Arnold LE, et al. Atomoxetine and parent training for children with autism and attention-deficit/hyperactivity disorder: a 24-week extension study. Journal of the American Academy of Child and Adolescent Psychiatry, 2016. https://doi.org/10.1016/j.jaac.2016.06.015 ; https://pubmed.ncbi.nlm.nih.gov/27663942/
- 24Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2006. https://doi.org/10.1097/01.chi.0000231976.28719.2a ; https://pubmed.ncbi.nlm.nih.gov/17003665/
- 25Scahill L, McCracken JT, King BH, et al. Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. American Journal of Psychiatry, 2015. https://doi.org/10.1176/appi.ajp.2015.15010055 ; https://pubmed.ncbi.nlm.nih.gov/26315981/
- 26Politte LC, Scahill L, Figueroa J, et al. A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures. Neuropsychopharmacology, 2018. https://doi.org/10.1038/s41386-018-0039-3 ; https://pubmed.ncbi.nlm.nih.gov/29540864/
- 27Joshi G, DiSalvo M, Wozniak J, et al. A prospective open-label trial of long-acting liquid methylphenidate for the treatment of attention deficit/hyperactivity disorder in intellectually capable adults with autism spectrum disorder. The World Journal of Biological Psychiatry, 2020. https://doi.org/10.1080/15622975.2019.1679392 ; https://pubmed.ncbi.nlm.nih.gov/31607204/
- 28Gupta N, Boyes D, Hanlon-Taylor H, et al. Systematic review: Safety and efficacy of atomoxetine in children and adolescents with autism spectrum disorder. JCPP Advances, 2026. https://doi.org/10.1002/jcv2.70022 ; https://pubmed.ncbi.nlm.nih.gov/41815758/